Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.

Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or "the Company") (NASDAQ: GILD) ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...